JP2014523918A - 樹状細胞に少なくとも一つの抗原を標的とするための手段を有する組成物 - Google Patents

樹状細胞に少なくとも一つの抗原を標的とするための手段を有する組成物 Download PDF

Info

Publication number
JP2014523918A
JP2014523918A JP2014522052A JP2014522052A JP2014523918A JP 2014523918 A JP2014523918 A JP 2014523918A JP 2014522052 A JP2014522052 A JP 2014522052A JP 2014522052 A JP2014522052 A JP 2014522052A JP 2014523918 A JP2014523918 A JP 2014523918A
Authority
JP
Japan
Prior art keywords
antigen
toxin
targeting
dendritic cells
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014522052A
Other languages
English (en)
Japanese (ja)
Inventor
タルトゥール，エリク
ジョアン，リュジェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut Curie
Universite Paris Descartes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut Curie
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut Curie, Universite Paris Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2014523918A publication Critical patent/JP2014523918A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2014522052A 2011-07-22 2012-07-23 樹状細胞に少なくとも一つの抗原を標的とするための手段を有する組成物 Pending JP2014523918A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305959.6 2011-07-22
EP11305959A EP2548571A1 (en) 2011-07-22 2011-07-22 Compositions having means for targeting at least one antigen to dendritic cells
PCT/EP2012/064425 WO2013014128A1 (en) 2011-07-22 2012-07-23 Compositions having means for targeting at least one antigen to dendritic cells

Publications (1)

Publication Number Publication Date
JP2014523918A true JP2014523918A (ja) 2014-09-18

Family

ID=46548478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014522052A Pending JP2014523918A (ja) 2011-07-22 2012-07-23 樹状細胞に少なくとも一つの抗原を標的とするための手段を有する組成物

Country Status (9)

Country Link
US (2) US20140199379A1 (enExample)
EP (2) EP2548571A1 (enExample)
JP (1) JP2014523918A (enExample)
CN (1) CN103796674A (enExample)
AU (1) AU2012288949B2 (enExample)
CA (1) CA2841036A1 (enExample)
IL (1) IL230525A0 (enExample)
IN (1) IN2014DN00078A (enExample)
WO (1) WO2013014128A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953287A1 (en) * 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN104277094A (zh) * 2014-07-04 2015-01-14 文康医疗技术（深圳）有限公司 Dc靶向肽及其应用
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA2986687A1 (en) * 2015-05-22 2016-12-01 Brian J. Czerniecki Manufacturing multi-dose injection ready dendritic cell vaccines
WO2016199904A1 (ja) * 2015-06-10 2016-12-15 国立大学法人東京大学 ワクチン用アジュバント、ワクチン、及び免疫誘導方法
US20190010236A1 (en) * 2015-12-29 2019-01-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for dectin-2 stimulation and cancer immunotherapy
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018203833A1 (en) * 2017-05-03 2018-11-08 Agency For Science, Technology And Research Methods for the stimulation of dendritic cell (dc) precursor population "pre-dc" and their uses thereof
WO2020245321A1 (en) * 2019-06-04 2020-12-10 Institut Curie METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用
CN115724992A (zh) * 2022-07-25 2023-03-03 江南大学 一种志贺毒素b亚基与抗原偶联物及其制备方法与应用
GB202411940D0 (en) * 2024-08-13 2024-09-25 Univ Exeter Anti-CLEC12A Antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
EP1229045A1 (en) 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
GB0524409D0 (en) 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines

Also Published As

Publication number Publication date
IN2014DN00078A (enExample) 2015-05-15
CA2841036A1 (en) 2013-01-31
CN103796674A (zh) 2014-05-14
AU2012288949A1 (en) 2013-04-11
AU2012288949B2 (en) 2014-05-01
EP2734225A1 (en) 2014-05-28
US20140199379A1 (en) 2014-07-17
US20170042994A1 (en) 2017-02-16
EP2548571A1 (en) 2013-01-23
WO2013014128A1 (en) 2013-01-31
IL230525A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
JP2014523918A (ja) 樹状細胞に少なくとも一つの抗原を標的とするための手段を有する組成物
US12344661B2 (en) Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
Thomann et al. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting
Cusi Applications of influenza virosomes as a delivery system
Renaudet et al. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity
CN102448485B (zh) 免疫原性组合物及其用途
KR102622188B1 (ko) 암 치료를 위한 면역원성 화합물
AU2002221519B2 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
Afzal et al. Structural engineering of flagellin as vaccine adjuvant: quest for the minimal domain of flagellin for TLR5 activation
Zhou et al. Multifunctional lipidated protein carrier with a Built-In adjuvant as a universal vaccine platform potently elevates immunogenicity of weak antigens
Ito et al. Antigen/adjuvant-displaying enveloped viral replica as a self-adjuvanting anti-breast-cancer vaccine candidate
Zheng et al. Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis
Lin et al. Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses
JP2001522235A (ja) ターゲッティング分子を用いた免疫応答の増強
Xu et al. Development of an enzyme-mediated, site-specific method to conjugate toll-like receptor 2 agonists onto protein antigens: toward a broadly protective, four component, group A streptococcal self-adjuvanting lipoprotein–fusion combination vaccine
US20090214598A1 (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
JP2003506314A (ja) 抗ウイルス性、抗寄生生物性または抗腫瘍性の細胞傷害性応答を引き起こす、抗原と一緒になった腸内細菌タンパク質ｏｍｐａの使用
US20230390369A1 (en) Chimeric antigen comprising the extracellular domain of pd-l1
US20100129383A1 (en) Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
CA2447585A1 (en) Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
Guy Adjuvants for protein-and carbohydrate-based vaccines
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
WO2025075173A1 (ja) 免疫原性キャリア及び免疫原性組成物
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell
BRPI0905094A2 (pt) imunoadjuvante, processo para obtenção de imunoadjuvante, composição farmaceutica e medicamento e uso do imunoadjuvante

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150310